72
Registered trials
32
Recruiting
35
Completed trials
39
Sponsors
24
Countries
Phase III:
32
Phase II/III:
1
Phase II:
25
Phase I/II:
3
Phase III/IV:
2
Phase IV:
7
Phase I (FiH):
2
Oversight events:
15 temporary halts
1 urgent safety measure
1 corrective measure
across 4 trials
View oversight register →
Indications tested
Hormone receptor positive HER2 negative breast cancer
8
Breast cancer
7
Breast cancer metastatic
4
HER2 positive breast cancer
3
Ovarian epithelial cancer
2
Hormone receptor positive breast cancer
2
Hormone receptor positive HER2 positive breast cancer
1
Non-small cell lung cancer metastatic
1
Neoadjuvant therapy
1
Ovarian cancer stage IV
1
Triple positive breast cancer
1
Colorectal cancer metastatic
1
Sponsors using this IMP
F. Hoffmann-La Roche AG
7
Unicancer
7
Novartis Pharma AG
6
Pfizer Inc.
5
AstraZeneca AB
4
Medica Scientia Innovation Research S.L.
4
Amsterdam UMC Stichting
2
European Organisation For Research And Treatment Of Cancer
2
Fundacion Grupo Espanol De Investigacion En Cancer De Mama
2
Karolinska University Hospital
2
Olema Pharmaceuticals Inc.
2
Region Oerebro Laen
2
All trials
72 total-
The OMNIMARA Trial Pending
-
The RED FLASH study Recruiting
Showing 1–24 of 72 trials